Danaher Names Sawyer Montgomery CEO, Co-Founders Get Equity

Why It Matters

The equity awards appear in Danaher’s press release only as “special equity incentive awards for key leadership members and founders,” with no figure attached. The Form 8-K states a target award value for four grants and share counts for two more.

Item 8.01 states there is no change to Danaher’s previously communicated third-quarter and full-year 2026 guidance. The next sentence states that the company expects to exclude the program’s stock-based compensation expense from Adjusted Diluted Net Earnings Per Share.

The grants the filing states in shares go to the company’s co-founders, Steven M. Rales, chairman of the board, and Mitchell P. Rales, chairman of the executive committee. A special committee of the board “comprising solely disinterested directors” recommended those awards on July 31, 2026, and the compensation committee approved them the same day.

Four grants carry a dollar figure, from $20,000,000 down

Item 5.02 states that Sawyer Montgomery will receive a Long-Term Growth Award with a target award value of $20,000,000, alongside an offer letter dated August 3, 2026. The compensation committee approved three more dollar-stated grants on July 31, 2026. Chief Financial Officer Matthew Gugino is to receive a Long-Term Growth Award with a target award value of $12,500,000, on the same terms. Christopher P. Riley, executive vice president of the Biotechnology Group, and Jose-Carlos Gutierrez-Ramos, senior vice president and chief science officer, are to receive restricted stock units at target award values of $8,000,000 and $2,625,000.

The filing describes Sawyer Montgomery’s award as part of “a broader program of special awards to key leaders,” so the recipients it names may not be the whole program. Each option grant it describes carries a per-share exercise price equal to the closing price of Danaher common stock on the New York Stock Exchange on the Grant Date. That date is August 4, 2026. The Market Context archive includes Mattel’s stock grant to a new brand president and Warner Music’s split of its chief financial officer role.

Four of the awards are scheduled to vest half in 2030, half in 2031

Sawyer Montgomery’s award, Gugino’s award and both co-founders’ grants share one vesting schedule. Half vests on the fourth anniversary of the August 4, 2026 grant date and half on the fifth, subject to continued employment through the applicable vesting date.

Item 8.01 states the program is intended to align the interests of Steven Rales, Mitchell Rales and Sawyer Montgomery, along with other senior leaders, with those of shareholders. The stated mechanism is “rewarding the achievement of upside potential and requiring a lengthy service period,” in the filing’s words.

Item 5.02 states that Sawyer Montgomery’s and Gugino’s awards accelerate on death or disability, and a prorated portion on a termination without cause after the first anniversary. Item 8.01 states the co-founders’ grants accelerate a prorated portion on death, disability or an involuntary termination without cause.

The restricted stock unit awards to Riley and Gutierrez-Ramos vest on shorter schedules. Riley’s vest 50% at 18 months and 50% at 30 months from the grant date. Gutierrez-Ramos’s vest in full at 12 months. Both are subject to continued employment through the vesting date.

Her offer letter sets her ongoing compensation separately. Effective October 1, 2026 it fixes an annual base salary rate of $1,500,000 and a target annual cash incentive opportunity equal to 200% of that base, prorated for 2026. It adds a long-term incentive award opportunity for 2027 with a target award value of $13,200,000.

Blair retires as chief executive officer on October 1, 2026

Blair leaves the chief executive role and the board on October 1, 2026, then stays a non-officer employee as senior advisor through December 31, 2026. He then serves as a non-employee consultant until March 31, 2027, at monthly fees equal to the current monthly rate of his base salary. During that consultancy period he is not eligible for cash bonuses or equity awards under the company’s incentive plans. Subject to continued employment through December 31, 2026, or his earlier death or disability, he stays eligible for a full 2026 annual cash incentive. It is based on his current target opportunity and actual company performance, at a personal payout percentage of 100%.

On the employment separation date he becomes entitled to twelve months of base salary at the current monthly rate and a lump sum equal to his current target annual cash incentive. He also becomes entitled to a lump-sum COBRA subsidy equal to twelve months of employer contributions toward his health coverage. Each requires his execution and non-revocation of a release of claims and a supplemental release, each within 30 days.

In the furnished press release, Steven Rales credits Blair with guiding Danaher and its 60,000-plus global associates through the COVID-19 pandemic. The same release credits Sawyer Montgomery with helping grow the diagnostics business from approximately $6.0 billion in revenue in 2017.

What to watch

1. Form 4 filings covering the August 4, 2026 grant date. Read the price column for the per-share exercise price, which this 8-K states only as a formula.

2. Danaher’s Form 10-Q for the third quarter of 2026, the first periodic report whose period contains the August 4, 2026 grant date. Read the share-based compensation line in the cash flow statement.

3. Danaher’s annual proxy statement covering fiscal year 2026. Read the Grants of Plan-Based Awards table for any of these grants to persons reported as named executive officers.